Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00044148 · ClinicalTrials.gov registry record · Phase 2
The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes
A Phase 2 study, sponsored by Chromaderm.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00044148: Completed Phase 2 study, sponsored by Chromaderm.
NCT00044148 is a Phase 2 study that has completed, run by Chromaderm. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00044148, a Phase 2 study, has completed, sponsored by Chromaderm.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The purpose of this study are to determine 1) Whether Ly333531 can reduce urinary albumin/creatinine excretion in patients with Type II diabetes and persistent albuminuria 2) Whether LY333531 reduces urinary TGF-B, 3) the safety of LY333531 and any side effects that may be associated with it.
Interventions
- DRUG LY333531
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-07-16 |
| Est. Completion | 2004-04-28 |
| Phase | Phase 2 |
What the finished NCT00044148 record still lists
NCT00044148 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which LY333531 is the first listed.
NCT00044148 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00044148 about?
NCT00044148 is a clinical study titled "The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes". The purpose of this study are to determine 1) Whether Ly333531 can reduce urinary albumin/creatinine excretion in patients with Type II diabetes and persistent albuminuria 2) Whether LY333531 reduces urinary TGF-B, 3) the safety of LY333531 and any side effects that may be associated with it.
What is the current status of trial NCT00044148?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-07-16. Estimated completion is 2004-04-28.
What interventions are being tested in trial NCT00044148?
The interventions under investigation include: LY333531 (DRUG).
Who is sponsoring clinical trial NCT00044148?
This trial is sponsored by Chromaderm, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI